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Abstract
Background: BRCA1–associated protein 1 (BAP1) is a tumor suppressor gene located on chromosome 3p21.
Germline BAP1 mutations have been recently associated with an increased risk of malignant mesothelioma, atypical
melanocytic tumors and other neoplasms. To answer the question if different germline BAP1 mutations may
predispose to a single syndrome with a wide phenotypic range or to distinct syndromes, we investigated the
presence of melanocytic tumors in two unrelated families (L and W) with germline BAP1 mutations and increased
risk of malignant mesothelioma.
Methods: Suspicious cutaneous lesions were clinically and pathologically characterized and compared to those
present in other families carrying BAP1 mutations. We then conducted a meta-analysis of all the studies reporting
BAP1-mutated families to survey cancer risk related to the germline BAP1 mutation (means were compared using
t-test and proportions were compared with Pearson χ2 test or two-tailed Fisher’s exact test).
Results: Melanocytic tumors: of the five members of the L family studied, four (80%) carried a germline BAP1
mutation (p.Gln684*) and also presented one or more atypical melanocytic tumors; of the seven members of W
family studied, all carried a germline BAP1 mutation (p.Pro147fs*48) and four of them (57%) presented one or more
atypical melanocytic tumors, that we propose to call “melanocytic BAP1-mutated atypical intradermal tumors”
(MBAITs). Meta-analysis: 118 individuals from seven unrelated families were selected and divided into a
BAP1-mutated cohort and a BAP1-non-mutated cohort. Malignant mesothelioma, uveal melanoma, cutaneous
melanoma, and MBAITs prevalence was significantly higher in the BAP1-mutated cohort (p≤ 0.001).
Conclusions: Germline BAP1 mutations are associated with a novel cancer syndrome characterized by malignant
mesothelioma, uveal melanoma, cutaneous melanoma and MBAITs, and possibly by other cancers. MBAITs provide
physicians with a marker to identify individuals who may carry germline BAP1 mutations and thus are at high risk of
developing associated cancers.
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Background
Hereditary cancer syndromes are caused by mutations
in genes conferring high relative risks of cancer among
carriers [1]. The majority of the hereditary cancer syn-
dromes are inherited in an autosomal dominant man-
ner and the cancers occur early in life. Remarkably,
benign mucocutaneous lesions (e.g. café-au-lait spots in
neurofibromatosis type I, hamartomas in Cowden syn-
drome, and hyperpigmented macules in Peutz–Jeghers
syndrome) are often the first clues that allow physicians
to diagnose patients with these syndromes [2]. BAP1
(BRCA1–associated protein 1) is a member of the ubi-
quitin C-terminal hydrolase subfamily of deubiquitinat-
ing enzymes that catalyze the removal of ubiquitin from
protein substrates [3], e.g. monoubiquitinated histone
H2A [4]. Also, a multi-protein complex containing
BAP1 is involved in regulation of cell transcription [5].
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We recently identified two unrelated families (L and
W) with germline BAP1 mutations and increased risk of
malignant mesothelioma (MM) and possibly other can-
cers [6]. In parallel with our study, Wiesner and collea-
gues reported germline BAP1 mutations in two
unrelated families with “atypical melanocytic tumors”
and other cancers [7]. In a subsequent paper, Wiesner
and colleagues called the same melanocytic lesions
“atypical Spitz tumors” (ASTs), but noted that in con-
trast to ASTs these lesions had a different histology and
were characterized by the presence of both BAP1 and
BRAF mutations [8]. BRAF mutations are indeed com-
mon in melanocytic nevi (80%) and in cutaneous mela-
nomas (CMs) (65%) but are rare in ASTs [8]. Other
investigators independently confirmed the association of
germline BAP1 mutations and other cancers in add-
itional families [9,10]. In two of these families, skin
lesions morphologically, histologically, and molecularly
similar to the previously reported “atypical melanocytic
tumors” or “ASTs” were investigated and identified but
instead called “nevoid melanoma-like melanocytic prolif-
erations” (NEMMPs) [10].
To verify if germline BAP1 mutations are associated
with distinct syndromes or with a single syndrome exhi-
biting a wide phenotypic range, we first investigated the
presence of melanocytic tumors in our two families and
compared them to those published in the literature, and
then conducted a pooled analysis of individuals from
studies reporting BAP1-mutated families to compare
cancer risk in the 63 mutated vs the 55 non-mutated
individuals from those families.
We demonstrate that germline BAP1 mutations are
associated with a novel cancer syndrome characterized
by MM, uveal melanoma (UVM), CM, MBAITs and pos-
sibly by other tumors.
Methods
Patients and family histories
We studied members of the L and W families. Written
and informed consent was obtained from all participants
in the study according to the guidelines set forth by the
Institutional Review Board of the University of Hawai‘i.
Family histories were collected through interviews, written
questionnaires, and medical and/or pathological reports.
Germline BAP1 sequencing
Genomic DNA was extracted from whole blood and
analyzed using bidirectional sequencing of the BAP1
gene in our Hawaii Cancer Consortium CLIA/CAP cer-
tified laboratory.
Clinical and pathological studies
BAP1-mutated family members were evaluated by a
board certified dermatologist specialized in melanocytic
lesions (L.K.F.). Biopsies from five members of L family
(L-III-18, L-IV-4, L-IV-5, L-IV-13, and L-IV-15) and
seven members of W family (W-III-4, W-IV-8, W-IV-9,
W-IV-12, W-IV-13, W-IV-21, and W-IV-25) were col-
lected. In total, 13 lesions were collected from the
L family members and 11 from the W family members.
A dermatoscopic analysis was conducted of all suspi-
cious lesions after their excision.
Immunohistochemistry (IHC) was performed on par-
affin tissue sections with a monoclonal antibody against
BAP1 (1:200, C-4, Santa Cruz Biotechnology) using
Leica-BOND III automated IHC and ISH system accord-
ing to a modified manufacturer protocol using Bond
Polymer Refine Detection kit (Leica Microsystems) fol-
lowing antigen retrieval Solution 1 (Leica Microsystems).
The pathological evaluation of the tissue sections and
the immune-staining were independently conducted
at the University of Hawai‘i and at the University of
Chicago with 100% diagnostic concordance.
Tumor tissue sections were microdissected with a laser
capture microscope (Molecular Machine Industries) by a
board certified dermatopathologist (C.A.L.). DNA was
extracted and purified with a QIAamp DNA FFPE Tissue
Kit (Qiagen) according to the manufacturer’s instruc-
tions. BRAF (exon15) mutations were detected by multi-
plex PCR amplification of tumor DNA, followed by
automated fluorescent labeling, hybridization to a Bio-
FilmChip Microarray, and signal detection using the
AutoGenomics INFINITY Analyzer (AutoGenomics).
Meta-analysis
To identify all reports of germline BAP1-mutated fam-
ilies, we searched the PubMed database using the search
terms “germline” and “BAP1”. This search yielded 11
results. The inclusion criteria were: at least two genera-
tions and five members tested for germline BAP1 muta-
tions, one positive germline BAP1 mutation found in at
least one member of the family, and cancer status
assessed for each of the tested members. Among the 11
results, four studies published between August 2011 and
April 2012 satisfied the inclusion criteria, with a total of
seven selected families [6,7,9,10]. Moreover, the findings
of this current paper were included in the analysis. We
asked the authors of the four selected papers for add-
itional data: we collected gender, age of death or age of
last follow up, germline BAP1 mutation result, all diag-
nosed cancers, and age of each cancer diagnosis. These
available data allowed us to avoid most of the problems
arising with formal meta-analyses and to conduct a
pooled analysis of the individual data. To assess if
germline BAP1 mutations were associated with an
increased risk of cancer or MBAITs, we built two
cohorts from these families: one cohort constituting
63 germline BAP1-mutated patients and the second
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cohort constituting 55 non-mutated patients. Both co-
hort numbers were higher than 30 cases, thus they
were considered as following a normal distribution.
Means were compared using the t-test if the Barlett’s
test for equal variances was non-significant; otherwise
means were compared by the Welch’s test. Proportions
were compared with Pearson χ2 test, or two-tailed
Fisher’s exact test when an expected number was
fewer than five. Because of the very small numbers for
each site of cancer, the odds ratio (OR) of only the
overall cancer risk was calculated with its 95% confi-
dence interval (CI). Statistical tests were performed
with STATA (version 12.0) software.
Results
We reviewed the published morphology and histology
and some of the original tissue sections from the pub-
lished melanocytic skin lesions [7-9]. In addition, we
investigated for the presence of these melanocytic
tumors in members of the BAP1-mutated families previ-
ously found to have developed MM and UVM [6]. These
tumors were indistinguishable. Thus, pathologists have
used different names to identify these pink to tan skin
tumors of about 0.2-1.0 cm in diameter, which macro-
scopically resemble dermal nevi, but that histologically
and at the molecular level do not fit any previous diag-
nostic nomenclature. In this paper we will use the term
MBAITs (Melanocytic BAP1-mutated Atypical Intrader-
mal Tumors) for all the described BAP1-mutated atyp-
ical melanocytic proliferations with similar histology and
molecular characterization that were previously diag-
nosed using various terminologies (Figure 1).
Specifically, we analyzed suspicious cutaneous tumors
from five members of L family and seven members of
W family. Of the five members of L family, four (80%)
presented one or more MBAITs. The age range of posi-
tively screened individuals was 36–64 years. One of
them positive for MBAITs (L-III-18) had already been
diagnosed with both MM and UVM.
Of the seven members of W family, four (57%) pre-
sented one or more MBAITs. The age range of the
screened individuals was 26–61 years. One of them, posi-
tive for MBAITs (W-III-04), had already been diagnosed
with MM. The individual W-IV-21, already diagnosed
with MM, resulted negative for MBAITs screening, but
reported a recently diagnosed breast carcinoma.
All patients communicated that all of the MBAITs
looked and behaved as benign (present for a long time,
not growing or changing).
Histologically, MBAITs presented as intradermal
lesions with large epithelioid and spindled melanocytes,
with marked cytologic atypia and pleomorphic, hyper-
chromatic nuclei, and they were often associated with a
nearby compound or intradermal nevus (Figure 2). The
large epithelioid and spindle cells (i.e., the MBAITs cells)
showed no mitotic activity, a finding confirmed by the
negative Ki67 immunostaining (not shown). Kamino
bodies were not identified. In the MBAITs cells –but not
in the nearby smaller nevus cells- , IHC showed negative
BAP1 nuclear staining with variable cytoplasmic stain-
ing, suggesting loss of heterozygosity (LOH) of the wild-
type BAP1 allele (Figure 2).
Of the five members of L family, four (80%) carried
the germline BAP1 mutation (p.Gln684*). The family
member L-IV-5 did not have MBAITs and was not
mutated in BAP1. All of the seven members of W family
carried the germline BAP1 mutations (p.Pro147fs*48).
BRAF genotyping was performed on all the nine diag-
nosed MBAITs and BRAFV600E mutations were identi-
fied in all of them, confirming the extremely high
prevalence of this mutation as originally reported by
Wiesner and colleagues [7], and confirmed by Njauw
and colleagues [10].
The characteristics of the pooled families are described
in Table 1. Among the seven families, 118 patients were
selected. The results of the meta-analysis are presented
in Table 2. The BAP1-mutated cohort included 63
patients and the BAP1-non-mutated cohort 55 patients.
The mean ages of follow up were comparable in both
cohorts (53.2 years, 95%CI: 49.0-57.4 in the BAP1
mutated cohort, 51.0 years, 95%CI: 46.3-55.8 in the non-
mutated cohort). The proportion of women was higher
in the BAP1-mutated cohort compared to the non-
mutated cohort (63.3% and 43.6% respectively, p = 0.034).
Figure 1 Clinical presentations of MBAITs. MBAITs have variable
clinical presentations including pink polypoid papules (1, from
shoulder of patient W-F1-IV-9), raised pink papules (2, from groin of
L-F1-IV-15), and lightly pigmented papules (3, from cheek of L-F1-IV-
4). These lesions were clinically difficult to distinguish from banal
dermal nevi, as pictured in (4), which shows a clinically similar lesion
also from the chest of the same patient pictured in (2).
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At this time we do not have an explanation for this
finding, although it appears possible that BAP1 muta-
tion may carry a higher risk of lethality in utero for
males.
The overall prevalence of cancer was significantly
higher in the BAP1-mutated cohort compared with the
non-mutated cohort (63.5% and 9.1% respectively,
p < 0.001). Five tumors were observed in the non-
mutated cohort: two prostate cancers, one breast cancer,
one Hodgkin’s lymphoma and one Non-Hodgkin’s
lymphoma. The odds ratio (OR) of cancer risk in the
germline BAP1-mutated cohort versus the non-mutated
cohort was 17.39 (95% CI: 6.07-49.83). MM, UVM, CM
and MBAITs prevalence was significantly higher in the
BAP1-mutated cohort compared with the non-mutated
cohort (Table 2). No significant difference was found be-
tween the two cohorts concerning the rates of other
cancers.
Discussion
We performed a meta-analysis of all the published stud-
ies with BAP1-mutated families. To avoid the overesti-
mation of the cancer risks estimates usually due to
publication bias in meta-analyses, we chose to compare
BAP1 mutated vs non-mutated patients from the same
families. We demonstrate that germline BAP1 mutations
are associated with a significant increased overall risk of
cancer and particularly of MM, UVM and CM (Table 2).
In addition, two thirds of patients from the germline
BAP1-mutated cohort presented MBAITs, while these
tumors were not detected in the non-mutated indivi-
duals. Our results reveal that germline BAP1 mutations
cause a novel autosomal dominant hereditary cancer
syndrome, the BAP1 cancer syndrome, characterized
predominantly by MM, UVM, CM and by MBAITs and
possibly by other cancers. In fact, because of the rela-
tively high incidence of carcinomas in the general popu-
lation, a larger number of BAP1-mutant family members
have to be studied before ruling out the possibility that
additional cancers are linked to the BAP1 cancer
syndrome.
Early diagnosis is crucial for curative resection of CM
and UVM. For its anatomical localization, MM is a
tumor in which early diagnosis is particularly difficult; it
is indeed often diagnosed in advanced stages when
patients have median survivals of 6–12 months. How-
ever, when MM patients are diagnosed at Stage 1a, sur-
vivals of five or more years are not uncommon [11].
Indeed, a high degree of suspicion allowed us to detect
four MM in the L and W families at an early stage and
these patients experienced survivals of 5–10 and, hope-
fully, many more years.
MBAITs provide physicians with a marker to identify
individuals who may carry germline BAP1 mutations
Figure 2 Histology and immunohistochemistry of MBAITs. Representative biopsy from individual W-III-04. The histologic examination
(hematoxylin and eosin, H/E, of the nevi at the low power (H&E, 4X Original Magnification) magnification shows an intradermal melanocytic
nevus with superficial nests and deeper single melanocytic units. This background melanocytic nevus shows maturation with depth. A second
distinct, central, circumscribed population of melanocytes is identified at the mid-reticular dermis (1). This second population of melanocytes on
higher power (H&E, 20X Original Magnification) shows variably sized, large epithelioid and spindled melanocytes. There is marked cytologic atypia
comprised of pleomorphic, hyperchromatic nuclei (2). The immunohistochemistry for BAP1 demonstrates distinct staining between the
background melanocytic nevus and the embedded clusters of atypical epithelioid melanocytes. Identified is strong nuclear positivity in the
background melanocytic nevus and negative nuclear staining in the large epithelioid cells (3: BAP-1, 20X Original Magnification). On higher
power, the background melanocytes show strong nuclear staining in this superficial nest (4: BAP-1, 40X Original Magnification). Large epithelioid
cells with their pleomorphic nuclei demonstrate negative nuclear staining with variable cytoplasmic staining (5: BAP-1, 40X Original
Magnification).
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and thus are at high risk of developing CM, UVM and
MM. We identified MBAITs among the majority of
germline BAP1 mutation carriers in the L and W fam-
ilies. Our meta-analysis demonstrates that the prevalence
of MBAITs is significantly higher in germline BAP1 mu-
tation carriers compared to controls. MBAITs have vari-
able papular macroscopic appearance similar to dermal
nevi; nevertheless they present histological (Figure 2),
immunohistochemical (Figure 2) and molecular (BAP1
and BRAF mutations) features that allow their
characterization in the broad spectrum of melanocytic
lesions. We debated how to call these tumors, and we
concluded that it was best to give them a new name to
make a clear distinction between these tumors, and
other melanocytic lesions, such as Spitz nevus and ASTs.
Briefly, Spitz nevus consists of proliferation of large
epithelioid or spindle shaped melanocytes, or a mixture
of the two. At all ages, spindle cells are the most com-
mon cell type. Spitz nevi composed wholly of epithelioid
cells occur mainly in early childhood. Spitz nevi go
through the same junctional, compound and intradermal
phases as common acquired nevi, but most are removed
when they are compound lesions (when they have an
epidermal and dermal component). Spitz nevi are
roughly symmetrical and at any given level (epidermis,
junction, upper dermis, lower dermis) the lesion shows
similar architecture and cell type from side to side. The
cellularity of the lesion and the size of the cells and their
nuclei decrease toward the base of the Spitz nevus (so
called maturation) and this is associated with loss of
proliferative activity that is instead often present in the
upper parts of the nevus. Also the architecture at the
base (deep aspect) is infiltrative rather than expansile/
pushing, the nevus cells lying dispersed between dermal
collagen. In addition there is no nevus associate with
them (unless it is part of a combined nevus). ATS are
Spitzoid lesions that have some features that overlap
with melanoma making the differential diagnosis chal-
lenging: for example, there is no maturation towards the
deeper part of the dermis, and instead the AST cells
show mitotic activity.
Instead, the tumors found in these BAP1 mutated
patients show large epithelioid clonal cells (that resemble
those found in Spitz nevus and in ASTs) but these cells
are present only in the dermis (there is no epidermal
component). In contrast to Spitz nevi there is no matur-
ation towards the deeper part of the dermis, and in con-
trast to ASTs, Ki67 stain (a marker of cell proliferation)
consistently showed absence of mitotic figures. In almost
all of these BAP1 associated tumors, it was possible to
Table 1 Characteristics of the pooled families






Family W [6] 12 12
Family L [6] 16 32
Family 1 [7] 4 3
Family 2 [7] 9 2
FUM036 [9] 8 1
Family 562 [10] 4 3
Family 729 [10] 10 2
Table 2 Comparisons of gender, age and cancer rates










Male 22 (36.7%) 31 (56.4%)
Female 38 (63.3%) 24 (43.6%) 0.034 -
Age of follow-up
Number known 46 42
Mean age (Std. Err.) 53.2 (2.1) 51.0 (2.3) 0.4851 -
At least 1 cancer
Yes 40 (63.5%) 5 (9.1%) 17.39
No 23 (36.5%) 50 (90.9%) <0.001 (6.07-49.83)
Malignant mesothelioma
Yes 13 (21.0%) 0 (0.0%)
No 49 (79.0%) 55 (100%) <0.001 -
Uveal melanoma
Yes 11 (17.7%) 0 (0.0%)
No 51 (82.3%) 55 (100%) 0.001 -
Cutaneous melanoma
Yes 8 (12.9%) 0 (0.0%)
No 54 (87.1%) 55 (100%) 0.007} -
MBAITs**
Yes 24 (66.7%) 0 (0.0%)
No 12 (33.3%) 12 (100%) <0.001 -
Lung cancer
Yes 3 (4.8%) 0 (0.0%)
No 59 (95.2%) 55 (100%) 0.246} -
Breast cancer***
Yes 3 (7.9%) 1 (4.1%)
No 35 (91.9%) 23 (95.9%) 0.621} -
Renal cancer
Yes 2 (3.3%) 0 (0.0%)
No 60 (96.7%) 55 (100%) 0.497} -
Abbreviations: OR: Odds Ratio; CI: confidence interval; *: 62 informative, 1
BAP1-mutated patient had cancer of unknown origin, **: calculated only in
individuals belonging to present study, ref. 7 and ref. 10, ***: calculated only in
women, -: not calculated; NS: non significant; Std. Err.: standard error;
}: two-tailed Fisher’s exact test.
Carbone et al. Journal of Translational Medicine 2012, 10:179 Page 5 of 7
http://www.translational-medicine.com/content/10/1/179
detect remnants of a nearby conventional intradermal or
compound nevus formed by smaller cells in close prox-
imity to the large epithelioid cells, a very unlikely finding
in Spitz and ASTs. In addition, at the cytophatological
level, the nuclei of the large clonal cells in these BAP1
tumors are hyperchromatic, while in Spitz and ATS, the
large cells have an open nuclear chromatin and a small
distinct nucleolus. Also no Kamino bodies –common in
Spitz- are detected in the BAP1 associated melanocytic
tumors. At the molecular level, these lesions are charac-
terized by BAP1 inactivation and almost always by con-
current BRAF mutation, features that are not found in
Spitz and ASTs. Finally, in contrast to AST that at times
mask a melanoma, these lesions are benign in appear-
ance and behavior and had a history of being stable in
morphology, per the patients, although it has been pro-
posed that these tumors, that here we propose to name
MBAITs, may rarely directly evolve into a CM, [7].
In summary, MBAITs have “Spitzoid features”, such as
large epitheliod and spindle cells, pleomorphisms, etc.,
but are sufficiently distinct morphologically, cytologically,
molecularly and clinically from ASTs that they should
not be lumped together. The entity of AST has become a
catch-all phrase to describe a very heterogenous group
of lesions clinically and histologically. This has resulted
in overly aggressive approaches to their management,
such as the use of sentinel lymph node biopsy. Mole-
cular genetic studies will ultimately help us divide the
entity of ASTs into subgroups based on genetics and
ultimately behavior. This progress will be valuable in
guiding clinical management. Therefore, we believe that
if we continue to lump different melanocytic lesions
(such as MBAITs) under the umbrella term of AST we
will miss an opportunity to help pathologists to identify
and classify this subgroup and to guide clinicians in
selecting patients who may need testing for BAP1
mutations.
The youngest individuals positively screened for
MBAITs in the L and W families were in their third and
fourth decades of life, but all of them described to us
these lesions as having been present for several years.
Accordingly, Wiesner et al. reported that in the BAP1-
mutant families they studied, MBAITs appeared during
the first two decades of life and increased in number
with age [7,8]. Therefore, MBAITs may exhibit anticipa-
tion of several years to the development of MM, CM
and UVM, the characteristic malignancies of the BAP1
cancer syndrome. Along the guidelines used for FAMM-
P families [12] we advise families with hereditary BAP1
mutation to have family members tested for mutant
gene carrier status at the age of ten and, if positive, to
begin routine screening with a total body dermatological
examination as family members may develop melanoma
at an early age. When these individuals become adults,
annual eye examinations (indirect ophthalmoscopy, etc.)
should be performed for early detection of UVM.
Conclusions
Physicians should become aware that papular cutaneous
tumors could be the first clinical manifestation of the
BAP1 cancer syndrome. Suspicious lesions should be
excised and evaluated by a pathologist. Pathologist also
must become aware of the histological characteristics
that characterize MBAITs from other intradermal mela-
nocytic tumors. In the presence of intradermal tumors
containing large epithelioid melanocytes, with marked
cytologic atypia and pleomorphic, hyperchromatic nu-
clei, BAP1 immuno-staining should be performed. In the
presence of negative nuclear BAP1 staining, the diagno-
sis of MBAIT is posed. Detection of BRAF mutations
may help diagnose this condition in cases of inconclusive
BAP1 staining. Next, genetic counseling should be
offered and germline DNA should be tested for BAP1
mutations to identify individuals and families at higher
risk for one or more of the neoplasms associated with
the BAP1 cancer syndrome. Germline BAP1 mutation
carriers can be targeted for early detection and therapy
that is associated with either a cure or improved
prognosis.
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